Results 151 to 160 of about 92,728 (309)

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

Phytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Chronic Lymphocytic Leukemia [electronic resource] : Methods and Protocols /

This book aims to provide scientists with tools and well-researched protocols to enable their research and to facilitate further progress in this common leukemia.
SpringerLink (Online service), Malek, Sami N.editor.edthttp://id.loc.gov/vocabulary/relators/edt   +1 more
core   +1 more source

Cuproptosis Inducers in Cancer Therapy: State of the Art and Challenges

The Chemical Record, EarlyView.
Cuproptosis is emerging as a distinct copper‐dependent cell death pathway, highlighting copper as a potential metabolic vulnerability in cancer. This review examines how coordination chemistry, redox regulation, and nanomaterial design shape Cu reactivity and therapeutic outcomes.
Chiara Ragusa, Valentina Oliveri
wiley   +1 more source

Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series

Blood Advances
Ellinor Goergen, Sandra Robrecht, Rudy Ligtvoet, Kirsten Fischer, Barbara Eichhorst, Petra Langerbeins, Michael Hallek   +6 more
doaj   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Nonthermal plasma approaches for combating implant‐associated infections: A compendious review

VIEW, EarlyView.
Implant‐associated infections pose serious clinical challenges. Non‐thermal plasma (NTP) modifications overcome this bottleneck in distinct ways relative to traditional sterilization methods. Gas‐phase plasmas generate highly energetic species, UV radiation and reactive oxygen/nitrogen species (RONS), which alter the implant surface properties.
A. M. Trimukhe, Satish Rojekar, Amol Gholap, K. Navaneetha Pandiyaraj, Mukesh Patekar, Claudia Riccardi, R. R. Deshmukh, Tomáš Kovářík, Kalim Deshmukh   +8 more
wiley   +1 more source

Advancing Immunotherapy in Chronic Lymphocytic Leukemia. [PDF]

Int J Mol Sci
Bieliński K, Wysocka A, Tyrna D, Robak T, Puła B.   +4 more
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source